.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,958,691

« Back to Dashboard

Details for Patent: 5,958,691

Title: High affinity nucleic acid ligands containing modified nucleotides
Abstract:Nucleic acid ligands containing modified nucleotides are described as are methods for producing such oligonucleotides. Such ligands enrich the chemical diversity of the candidate mixture for the SELEX process. Specific examples are provided of nucleic acids containing nucleotides modified at the 2'- and 5-position. Specific 2-OH and 2'-NH.sub.2 modified RNA ligands to thrombin are described.
Inventor(s): Pieken; Wolfgang (Longmont, CO), Tasset; Diane (Boulder, CO), Janjic; Nebojsa (Lafayette, CO), Gold; Larry (Boulder, CO), Kirschenheuter; Gary P. (Arvada, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Aug 25, 1997
Application Number:08/918,304
Claims:1. A method for identifying nucleic acid ligands comprising a modified nucleotide to a target molecule comprising:

a) preparing a candidate mixture of single-stranded nucleic acids wherein each nucleic acid of said candidate mixture comprises a modified nucleotide;

b) contacting the candidate mixture with said target molecule;

c) partitioning the nucleic acids having an increased affinity to the target molecule relative to the candidate mixture from the remainder of the candidate mixture; and

d) amplifying the increased affinity nucleic acids, in vitro, to yield a ligand-enriched mixture of nucleic acids, whereby nucleic acid ligands comprising modified nucleotides of the target molecule are identified.

2. The method of claim 1 further comprising e) repeating steps c) and d).

3. The method of claim 1 wherein said single-stranded nucleic acids are selected from the group consisting of single-stranded DNA and single-stranded RNA.

4. The method of claim 1 wherein said modified nucleotides have been chemically modified at the ribose and/or phosphate and/or base positions.

5. A nucleic acid ligand comprising a modified nucleotide to a target molecule, wherein said nucleic acid is comprised of a non-naturally occurring nucleic acid having a specific binding affinity for a target molecule, said target molecule being a three dimensional chemical structure other than a polynucleotide that binds to said nucleic acid ligand through a mechanism which predominantly depends on Watson/Crick base pairing or triple helix binding, wherein said nucleic acid ligand is not a nucleic acid having the known physiological function of being bound by the target molecule, obtained by the process of identifying a nucleic acid ligand of a target from a candidate mixture of nucleic acids wherein each nucleic acid of said candidate mixture comprises a modified nucleotide, said process comprising:

(a) contacting the candidate mixture with said target molecule;

(b) partitioning the nucleic acids having an increased affinity to the target molecule relative to the candidate mixture from the remainder of the candidate mixture; and

(c) amplifying the increased affinity nucleic acids, in vitro, to yield a ligand-enriched mixture of nucleic acids, whereby nucleic acid ligands comprising modified nucleotides of the target molecule are identified.

6. The nucleic acid ligand of claim 5 wherein said nucleic acid is selected from the group consisting of single-stranded RNA, double-stranded RNA, single-stranded DNA and double-stranded DNA.

7. The nucleic acid ligand of claim 5 wherein said nucleic acid comprises one or more or a combination of nucleotides which have been chemically modified at the ribose and/or phosphate and/or base positions.

8. The nucleic acid ligand of claim 7 wherein said nucleotide is modified at the 2'- or 5- position.

9. The nucleic acid ligand of claim 8 wherein said 2'-position modification to said nucleotide is a 2'-amino modification.

10. The nucleic acid ligand of claim 8 wherein said 2'-position modification to said nucleotide is a 2'-fluoro modification.

11. The nucleic acid ligand of claim 8 wherein said 5-position modified nucleotide is selected from the group consisting of 5-(3-aminoallyl)uridine triphosphate (5-AA-UTP), 5-fluorescein-12-uridine triphosphate (5-F-12-UTP), 5-digoxygenin-11-uridine triphosphate (5-Dig-11-UTP), and 5-bromouridine triphosphate (5-Br-UTP).

12. The nucleic acid ligand of claim 8 wherein said modified nucleotide is selected from the group consisting of a 2'-position modified pyrimidine and a 5-position modified pyrimidine.

13. The nucleic acid ligand of claim 9 wherein said modified nucleotide is selected from the group consisting of a 2'-amino pyrimidine and a 2'-amino purine.

14. The nucleic acid ligand of claim 9 wherein said modified nucleotide is selected from the group consisting of a 2'-fluoro pyrimidine and a 2'-fluoro purine.

15. A nucleic acid ligand comprising a modified nucleotide to a target molecule, wherein said nucleic acid is comprised of a non-naturally occurring nucleic acid having a specific binding affinity for a target molecule, such target molecule being a three dimensional chemical structure other than a polynucleotide that binds to said nucleic acid ligand through a mechanism which predominantly depends on Watson/Crick base pairing or triple helix binding, wherein said nucleic acid ligand is not a nucleic acid having the known physiological function of being bound by the target molecule.

16. The nucleic acid ligand of claim 15 wherein said nucleic acid is selected from the group consisting of single-stranded RNA, double-stranded RNA, single-stranded DNA and double-stranded DNA.

17. The nucleic acid ligand of claim 15 wherein said nucleic acid comprises one or more or a combination of nucleotides which have been chemically modified at the ribose and/or phosphate and/or base positions.

18. The nucleic acid ligand of claim 17 wherein said nucleotide is modified at the 2'- or 5- position.

19. The nucleic acid ligand of claim 18 wherein said 2'-position modification to said nucleotide is a 2'-amino modification.

20. The nucleic acid ligand of claim 18 wherein said 2'-position modification to said nucleotide is a 2'-fluoro modification.

21. The nucleic acid ligand of claim 18 wherein said 5-position modified nucleotide is selected from the group consisting of 5-(3-aminoallyl)uridine triphosphate (5-AA-UTP), 5-fluorescein-12-uridine triphosphate (5-F-12-UTP), 5-digoxygenin-11-uridine triphosphate (5-Dig-11-UTP), and 5-bromouridine triphosphate (5-Br-UTP).

22. The nucleic acid ligand of claim 18 wherein said modified nucleotide is selected from the group consisting of a 2'-position modified pyrimidine and a 5-position modified pyrimidine.

23. The nucleic acid ligand of claim 19 wherein said modified nucleotide is selected from the group consisting of a 2'-amino pyrimidine and a 2'-amino purine.

24. The nucleic acid ligand of claim 19 wherein said modified nucleotide is selected from the group consisting of a 2'-fluoro pyrimidine and a 2'-fluoro purine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc